Back to Search
Start Over
Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): A multicentre randomised controlled effectiveness trial
- Source :
- The Lancet. 384(9948)
- Publication Year :
- 2014
-
Abstract
- BACKGROUND: Medical conditions are often complicated by major depression, with consequent additional impairment of quality of life. We aimed to compare the effectiveness of an integrated treatment programme for major depression in patients with cancer (depression care for people with cancer) with usual care. METHODS: SMaRT Oncology-2 is a parallel-group, multicentre, randomised controlled effectiveness trial. We enrolled outpatients with major depression from three cancer centres and their associated clinics in Scotland, UK. Participants were randomly assigned in a 1:1 ratio to the depression care for people with cancer intervention or usual care, with stratification (by trial centre) and minimisation (by age, primary cancer, and sex) with allocation concealment. Depression care for people with cancer is a manualised, multicomponent collaborative care treatment that is delivered systematically by a team of cancer nurses and psychiatrists in collaboration with primary care physicians. Usual care is provided by primary care physicians. Outcome data were collected up until 48 weeks. The primary outcome was treatment response (≥50% reduction in Symptom Checklist Depression Scale [SCL-20] score, range 0-4) at 24 weeks. Trial statisticians and data collection staff were masked to treatment allocation, but participants could not be masked to the allocations. Analyses were by intention to treat. This trial is registered with Current Controlled Trials, number ISRCTN40568538. FINDINGS: 500 participants were enrolled between May 12, 2008, and May 13, 2011; 253 were randomly allocated to depression care for people with cancer and 247 to usual care. 143 (62%) of 231 participants in the depression care for people with cancer group and 40 (17%) of 231 in the usual care group responded to treatment: absolute difference 45% (95% CI 37-53), adjusted odds ratio 8·5 (95% CI 5·5-13·4), p
- Subjects :
- Adult
Male
medicine.medical_specialty
MEDLINE
Collaborative Care
law.invention
Young Adult
Randomized controlled trial
Ambulatory care
law
Neoplasms
Medicine
Humans
Young adult
Aged
Aged, 80 and over
Patient Care Team
Analysis of Variance
Depressive Disorder, Major
Intention-to-treat analysis
business.industry
Delivery of Health Care, Integrated
General Medicine
Odds ratio
Middle Aged
Patient Acceptance of Health Care
Checklist
Antidepressive Agents
Neoadjuvant Therapy
Psychotherapy
Treatment Outcome
Physical therapy
Female
business
Subjects
Details
- Language :
- English
- ISSN :
- 1474547X and 01406736
- Volume :
- 384
- Issue :
- 9948
- Database :
- OpenAIRE
- Journal :
- The Lancet
- Accession number :
- edsair.doi.dedup.....1b448209e0a8e0883fc00cf590d70def